Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Cell-Free SHOX2 DNA Methylation in Blood as a Molecular Staging Parameter for Risk Stratification in Renal Cell Carcinoma Patients: A Prospective Observational Cohort Study.

Jung M, Ellinger J, Gevensleben H, Syring I, Lüders C, de Vos L, Pützer S, Bootz F, Landsberg J, Kristiansen G, Dietrich D.

Clin Chem. 2019 Jan 9. pii: clinchem.2018.297549. doi: 10.1373/clinchem.2018.297549. [Epub ahead of print]

PMID:
30626634
2.

The knockdown of the Mediator complex subunit MED15 restrains urothelial bladder cancer cells' malignancy.

Syring I, Weiten R, Müller T, Schmidt D, Steiner S, Kristiansen G, Müller SC, Ellinger J.

Oncol Lett. 2018 Sep;16(3):3013-3021. doi: 10.3892/ol.2018.9014. Epub 2018 Jun 25.

3.

Influence of Body Mass Index on Clinical Outcome Parameters, Complication Rate and Survival after Radical Cystectomy: Evidence from a Prospective European Multicentre Study.

Gierth M, Zeman F, Denzinger S, Vetterlein MW, Fisch M, Bastian PJ, Syring I, Ellinger J, Müller SC, Herrmann E, Gilfrich C, May M, Pycha A, Wagenlehner FM, Vallo S, Bartsch G, Haferkamp A, Grimm MO, Roigas J, Protzel C, Hakenberg OW, Fritsche HM, Burger M, Aziz A, Mayr R.

Urol Int. 2018;101(1):16-24. doi: 10.1159/000488466. Epub 2018 May 2.

PMID:
29719296
4.

The knockdown of the mediator complex subunit MED30 suppresses the proliferation and migration of renal cell carcinoma cells.

Syring I, Weiten R, Müller T, Schmidt D, Steiner S, Müller SC, Kristiansen G, Ellinger J.

Ann Diagn Pathol. 2018 Jun;34:18-26. doi: 10.1016/j.anndiagpath.2017.12.008. Epub 2017 Dec 20.

PMID:
29661722
5.

The Mediator complex subunit MED15, a promoter of tumour progression and metastatic spread in renal cell carcinoma.

Weiten R, Müller T, Schmidt D, Steiner S, Kristiansen G, Müller SC, Ellinger J, Syring I.

Cancer Biomark. 2018;21(4):839-847. doi: 10.3233/CBM-170757.

PMID:
29400661
6.

The Contrasting Role of the Mediator Subunit MED30 in the Progression of Bladder Cancer.

Syring I, Weiten R, Müller T, Schmidt D, Steiner S, Kristiansen G, Müller SC, Ellinger J.

Anticancer Res. 2017 Dec;37(12):6685-6695.

PMID:
29187445
7.

Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression.

Klümper N, Syring I, Vogel W, Schmidt D, Müller SC, Ellinger J, Shaikhibrahim Z, Brägelmann J, Perner S.

Front Med (Lausanne). 2017 Mar 17;4:30. doi: 10.3389/fmed.2017.00030. eCollection 2017.

8.

MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling.

Offermann A, Vlasic I, Syring I, Vogel W, Ruiz C, Zellweger T, Rentsch CA, Hagedorn S, Behrends J, Nowak M, Merseburger A, Bubendorf L, Kirfel J, Duensing S, Shaikhibrahim Z, Perner S.

Oncotarget. 2017 Jan 31;8(5):7964-7976. doi: 10.18632/oncotarget.13860.

9.

Pan-Cancer Analysis of the Mediator Complex Transcriptome Identifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate Cancer.

Brägelmann J, Klümper N, Offermann A, von Mässenhausen A, Böhm D, Deng M, Queisser A, Sanders C, Syring I, Merseburger AS, Vogel W, Sievers E, Vlasic I, Carlsson J, Andrén O, Brossart P, Duensing S, Svensson MA, Shaikhibrahim Z, Kirfel J, Perner S.

Clin Cancer Res. 2017 Apr 1;23(7):1829-1840. doi: 10.1158/1078-0432.CCR-16-0094. Epub 2016 Sep 27.

10.

Comprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types.

Syring I, Klümper N, Offermann A, Braun M, Deng M, Boehm D, Queisser A, von Mässenhausen A, Brägelmann J, Vogel W, Schmidt D, Majores M, Schindler A, Kristiansen G, Müller SC, Ellinger J, Shaikhibrahim Z, Perner S.

Oncotarget. 2016 Apr 26;7(17):23043-55. doi: 10.18632/oncotarget.8469.

11.

Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma.

Schrödter S, Braun M, Syring I, Klümper N, Deng M, Schmidt D, Perner S, Müller SC, Ellinger J.

Mol Cancer. 2016 Feb 2;15:10. doi: 10.1186/s12943-016-0495-5.

12.

NDUFA4 expression in clear cell renal cell carcinoma is predictive for cancer-specific survival.

Müller FE, Braun M, Syring I, Klümper N, Schmidt D, Perner S, Hauser S, Müller SC, Ellinger J.

Am J Cancer Res. 2015 Aug 15;5(9):2816-22. eCollection 2015.

13.

The long non-coding RNA lnc-ZNF180-2 is a prognostic biomarker in patients with clear cell renal cell carcinoma.

Ellinger J, Alam J, Rothenburg J, Deng M, Schmidt D, Syring I, Miersch H, Perner S, Müller SC.

Am J Cancer Res. 2015 Aug 15;5(9):2799-807. eCollection 2015.

14.

Differential expression of Mediator complex subunit MED15 in testicular germ cell tumors.

Klümper N, Syring I, Offermann A, Shaikhibrahim Z, Vogel W, Müller SC, Ellinger J, Strauß A, Radzun HJ, Ströbel P, Brägelmann J, Perner S, Bremmer F.

Diagn Pathol. 2015 Sep 17;10:165. doi: 10.1186/s13000-015-0398-6.

15.

Identification of novel long non-coding RNAs in clear cell renal cell carcinoma.

Blondeau JJ, Deng M, Syring I, Schrödter S, Schmidt D, Perner S, Müller SC, Ellinger J.

Clin Epigenetics. 2015 Feb 8;7:10. doi: 10.1186/s13148-015-0047-7. eCollection 2015.

16.

Prostaglandin receptors EP1-4 as a potential marker for clinical outcome in urothelial bladder cancer.

von der Emde L, Goltz D, Latz S, Müller SC, Kristiansen G, Ellinger J, Syring I.

Am J Cancer Res. 2014 Nov 19;4(6):952-62. eCollection 2014.

17.

Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer.

Syring I, Bartels J, Holdenrieder S, Kristiansen G, Müller SC, Ellinger J.

J Urol. 2015 Jan;193(1):331-7. doi: 10.1016/j.juro.2014.07.010. Epub 2014 Jul 18.

PMID:
25046619
18.

MED12 overexpression is a frequent event in castration-resistant prostate cancer.

Shaikhibrahim Z, Offermann A, Braun M, Menon R, Syring I, Nowak M, Halbach R, Vogel W, Ruiz C, Zellweger T, Rentsch CA, Svensson M, Andren O, Bubendorf L, Biskup S, Duensing S, Kirfel J, Perner S.

Endocr Relat Cancer. 2014 Aug;21(4):663-75. doi: 10.1530/ERC-14-0171. Epub 2014 Jun 17.

PMID:
24938407
19.

[Prostate surgery within residency programs in urology].

Bründl J, Zengerling F, Borgmann H, Syring I.

Urologe A. 2014 Mar;53(3):379-81. doi: 10.1007/s00120-014-3424-5. German. No abstract available.

PMID:
24556710
20.

[Coating with plasma-deposited functionalized diamond-like carbon to decrease encrustations on urological implants].

Laube N, Kleinen L, Böde U, Fisang C, Meissner A, Bradenahl J, Syring I, Busch H, Pinkowski W, Müller SC.

Urologe A. 2007 Sep;46(9):1249-51. German.

PMID:
17634911

Supplemental Content

Loading ...
Support Center